| Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity. | |
| | |
MedLine Citation:
|
PMID: 20046162 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The importance of renin-angiotensin aldosterone system (RAAS) in cardiovascular and renal diseases has long ago been recognized. However despite the availability of many effective drugs, such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers, RAAS blockade is incomplete in several patients with consequent uncontrolled high blood pressure and not efficacy cardiovascular and renal protection. Aliskiren is a new renin inhibitor that block the RAAS at its origin. Recent studies suggest that Aliskiren reduces blood pressure, inhibits plasma renin activity and attenuates renal damage in diabetic patients with nephropathy. This review summarized the results of the more important studies performed in hypertensive and diabetic patients in which Aliskiren showed to be a safe and effective antihypertensive agent that can be used in monotherapy or in combination with other drugs to provide additional options to improve blood pressure control. |
| | |
Authors:
|
M Dalla Vestra; N Simioni; A Masiero |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Minerva endocrinologica Volume: 34 ISSN: 0391-1977 ISO Abbreviation: Minerva Endocrinol. Publication Date: 2009 Dec |
Date Detail:
|
Created Date: 2010-01-04 Completed Date: 2010-05-11 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8406505 Medline TA: Minerva Endocrinol Country: Italy |
Other Details:
|
Languages: eng Pagination: 333-8 Citation Subset: IM |
Affiliation:
|
Cittadella General Hospital, Padua, Italy. dallav@libero.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aldosterone
/
physiology Amides / administration & dosage, adverse effects, pharmacology, therapeutic use* Angiotensin II Type 1 Receptor Blockers / administration & dosage, therapeutic use Angiotensin-Converting Enzyme Inhibitors / administration & dosage, therapeutic use Antihypertensive Agents / administration & dosage, adverse effects, pharmacology, therapeutic use* Clinical Trials as Topic / statistics & numerical data Diabetic Nephropathies / drug therapy, prevention & control Double-Blind Method Drug Therapy, Combination Fumarates / administration & dosage, adverse effects, pharmacology, therapeutic use* Humans Hypertension / drug therapy Randomized Controlled Trials as Topic / statistics & numerical data Renin / antagonists & inhibitors* Renin-Angiotensin System / drug effects*, physiology |
| Chemical | |
Reg. No./Substance:
|
0/Amides; 0/Angiotensin II Type 1 Receptor Blockers; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/Fumarates; 0/aliskiren; 52-39-1/Aldosterone; EC 3.4.23.15/Renin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Male osteoporosis.
Next Document: Seroprevalence of human brucellosis among the population at risk in rural area.